Quince Therapeutics holds special shareholder meeting
QNCX•Quince Therapeutics said shareholders approved share issuances tied to Series C preferred stock and related warrants or options, raised authorized common shares to 275 million from 250 million, and adopted two 2026 benefit plans.
1. Shareholder approvals
At its Oct. 6, 2026, special meeting, Quince Therapeutics shareholders authorized common share issuances tied to Series C Non-Voting Convertible Preferred Stock and related warrants or options, and a separate issuance tied to Series C Preferred Stock and related warrants from a private placement. They also approved an amendment increasing authorized common shares to 275 million from 250 million, effective Oct. 6, and adopted the 2026 equity incentive plan and 2026 employee stock purchase plan.
